Iovance Biotherapeutics (IOVA)
(Delayed Data from NSDQ)
$10.17 USD
-0.25 (-2.40%)
Updated Sep 18, 2024 03:59 PM ET
After-Market: $10.15 -0.02 (-0.20%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Company Summary
San Carlos, CA-based Iovance Biotherapeutics is a commercial-stage pharmaceutical company primarily focused on developing and commercializing novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 (“Gen 2”) tumor-infiltrating lymphocyte ("TIL"), which harnesses the power of a patient’s immune system to eradicate cancer cells. The Gen 2 process is currently in use in almost all studies in which the company manufactures TIL products, including lifileucel and LN-145. The company is also focused on developing a Generation 3 TIL.
In February 2024, Iovance received accelerated approval from the FDA for TIL therapy Amtagvi (...
Company Summary
San Carlos, CA-based Iovance Biotherapeutics is a commercial-stage pharmaceutical company primarily focused on developing and commercializing novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 (“Gen 2”) tumor-infiltrating lymphocyte ("TIL"), which harnesses the power of a patient’s immune system to eradicate cancer cells. The Gen 2 process is currently in use in almost all studies in which the company manufactures TIL products, including lifileucel and LN-145. The company is also focused on developing a Generation 3 TIL.
In February 2024, Iovance received accelerated approval from the FDA for TIL therapy Amtagvi (lifileucel) for the treatment of adult patients with advanced melanoma previously treated with a PD-1 and targeted therapy. The drug is also being studied in separate clinical studies for treating cervical cancer, head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) indications.
In May 2023, Iovance acquired worldwide rights to an FDA-approved interleukin-2 (IL-2) product, Proleukin (aldesleukin), from U.K.-based Clinigen Limited, for £166.7 million (around $200 million).The company will pay double-digit royalties on global Proleukin sales to Clingen.
Iovance also has an early-stage, non-genetically modified, polyclonal T cell product candidate, IOV-2001, which is being developed for chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL). The company is also developing other oncology candidates in collaboration with academic institutions. In January 2020, the company in-licensed an antibody cytokine engrafted protein, IOV-3001, from Novartis.
Iovance generated total revenues worth $1.2 million in 2023. In the year-ago period, it did not record any revenues.
General Information
Iovance Biotherapeutics, Inc
825 INDUSTRIAL ROAD SUITE 400
SAN CARLOS, CA 94070
Phone: 650-260-7120
Fax: NA
Email: ir@iovance.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/5/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.31 |
Current Year EPS Consensus Estimate | -1.27 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 11/5/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 10.42 |
52 Week High | 18.33 |
52 Week Low | 3.21 |
Beta | 0.63 |
20 Day Moving Average | 5,831,034.50 |
Target Price Consensus | 24.42 |
4 Week | -7.71 |
12 Week | 23.31 |
YTD | 28.17 |
4 Week | -8.32 |
12 Week | 19.70 |
YTD | 8.50 |
Shares Outstanding (millions) | 279.83 |
Market Capitalization (millions) | 2,915.86 |
Short Ratio | NA |
Last Split Date | 9/26/2013 |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | 27.66% |
vs. Previous Quarter | 19.05% |
vs. Previous Year | 12,969.75% |
vs. Previous Quarter | 4,250.49% |
Price/Book | 3.79 |
Price/Cash Flow | NA |
Price / Sales | 88.97 |
6/30/24 | -65.04 |
3/31/24 | -71.45 |
12/31/23 | -70.93 |
6/30/24 | -50.79 |
3/31/24 | -55.17 |
12/31/23 | -55.25 |
6/30/24 | 5.15 |
3/31/24 | 4.63 |
12/31/23 | 2.79 |
6/30/24 | 4.85 |
3/31/24 | 4.42 |
12/31/23 | 2.70 |
6/30/24 | -1,343.27 |
3/31/24 | -23,615.70 |
12/31/23 | NA |
6/30/24 | -1,343.27 |
3/31/24 | -23,615.70 |
12/31/23 | NA |
6/30/24 | -1,361.17 |
3/31/24 | -23,872.37 |
12/31/23 | -37,638.01 |
6/30/24 | 2.75 |
3/31/24 | 2.43 |
12/31/23 | 2.28 |
6/30/24 | 2.91 |
3/31/24 | 1.54 |
12/31/23 | 1.47 |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
12/31/23 | 0.00 |
6/30/24 | 0.13 |
3/31/24 | 0.15 |
12/31/23 | 0.17 |